The impact of medicare part D on hospitalization rates

Health Services Research

Volumn 46, Issue 4, 2011, Pages 1022-1038

  Afendulis, Christopher C ^a   He, Yulei ^a   Zaslavsky, Alan M ^a   Chernew, Michael E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

hospitalization; Medicare; prescription drugs

Indexed keywords

ADULT; AGED; AMBULATORY CARE; ARTICLE; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION COST; HUMAN; MEDICARE; PRESCRIPTION; UNITED STATES;

AGED; CHRONIC DISEASE; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; MEDICARE PART D; MEDICATION ADHERENCE; MIDDLE AGED; UNITED STATES;

EID: 79960090156     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/j.1475-6773.2011.01244.x     Document Type: Article

References (30)

1. Ai, C., and, E. C. Norton,. 2003. " Interaction Terms in Logit and Probit Models. Economics Letters 80 (1): 123-29. (Pubitemid 36598410)
2. Bertrand, M., E. Duflo, and, S. Mullainathan,. 2004. " How Much Should We Trust Differences-in-Differences Estimates? Quarterly Journal of Economics 119 (1): 249-75. (Pubitemid 38361206)
3. Beta-blocker Heart Attack Study Group. 1983. " A Randomized Trial of Propranolol in Patients with Acute Myocardial Infarction. II. Morbidity Results. Journal of American Medical Association 250: 2814-19.
4. Bindman, A. B., K. Grumbach, D. Osmond, M. Komaromy, K. Vranizan, N. Lurie, J. Billings, and, A. Stewart,. 1995. " Preventable Hospitalizations and Access to Health Care." 274 (4): 305-11.
5. Brophy, J. M., L. Joseph, and, J. L. Rouleau,. 2001. " Beta-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine 134: 550-60.
6. Centers for Medicare and Medicaid Services (CMS). 2009. "State County Health Plans, Reports, Files and Data" [accessed on April 13, 2010]. Available at http://www.cms.gov/HealthPlanRepFileData/02-SC.asp
7. Centers for Medicare and Medicaid Services (CMS). 2010. "CMS Guide to Requests for Medicare Part D Prescription Drug Event (PDE) Data, Version 3.0" [accessed on April 13, 2010]. Available at http://www.cms.hhs.gov/ PrescriptionDrugCovGenIn/08-PartDData.asp
8. The EURopean Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery disease Investigators. 2003. " Efficacy of Perindopril in Reduction of Cardiovascular Events among Patients with Stable Coronary Artery Disease: Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial (the EUROPA Study). Lancet 362: 782-88.
9. Fisher, E. S., D. E. Wennberg, T. A. Stukel, D. J. Gottlieb, F. L. Lucas, and, E. L. Pinder,. 2003. " The Implications of Regional Variations in Medicare Spending. Part 1: The Content, Quality, and Accessibility of Care. Annals of Internal Medicine 138 (4): 273-87.
10. Fung, V., C. M. Mangione, H. Jie, N. Turk, E. S. Quiter, J. A. Schmittdiel, and, J. Hsu,. 2010. " Falling into the Coverage Gap: Part D Drug Costs and Adherence for Medicare Advantage Prescription Drug Plan Beneficiaries with Diabetes. Health Services Research 45 (2): 355-75.
11. Goldman, D. P., G. F. Joyce, and, Y. Zheng,. 2007. " Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health. Journal of American Medical Association 298 (1): 61-9.
12. The Heart Outcomes Prevention Evaluation Study Investigators. 2000. " Effects of an Angiotensin Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine 342: 145-53.
13. Heart Protection Study Collaborative Group. 2002. " MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-Risk Individuals: A Randomised, Placebo-Controlled Trial. Lancet 360: 7-22.
14. LaRosa, J. C., S. M. Grundy, D. D. Waters, C. Shear, P. Barter, J. C. Fruchart, A. M. Gotto, H. Greten, J. J. Kastelein, J. Shepherd, and, N. K. Wenger,. 2005. " Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Journal of Medicine 352 (14): 1425-35. (Pubitemid 40471450)
15. Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. 1998. " Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine 339: 1349-57.
16. Pear, R., 2006. "Renewed Worries on Medicare Drug Plans."New York Times, December 5.
17. Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, B. R. Davis, and, E. Braunwald,. 1996. " The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. New England Journal of Medicine 335: 1001-09. (Pubitemid 26338729)
18. Schneeweiss, S., A. R. Patrick, A. Pedan, L. Varasteh, R. Levin, N. Liu, and, W. H. Shrank,. 2009. " The Effect of Medicare Part D Coverage on Drug Use and Cost Sharing among Seniors without Prior Drug Benefits. Health Affairs 28 (2): w305-16.
19. Sokol, M. C., K. A. McGuigan, R. R. Verbrugge, and, R. S. Epstein,. 2005. " Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost. Medical Care 43 (6): 521-30. (Pubitemid 40847288)
20. The SOLVD Investigators. 1991. " Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fraction and Congestive Heart Failure. New England Journal of Medicine 325: 293-302.
21. The SOLVD Investigators. 1992. " Effect of Enalapril on Mortality and the Development of Heart Failure I Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. New England Journal of Medicine 327: 685-91.
22. StataCorp, L. P., 2007. Stata (release 9.2). College Station, TX: StataCorp LP.
23. Stuart, B. C., J. A. Doshi, and, J. V. Terza,. 2009. " Assessing the Impact of Drug Use on Hospital Costs. Health Service Research 44 (1): 128-44.
24. United States Bureau of the Census. 2005. "Health Insurance Coverage Status by Age, Race, Hispanic Origin, Sex and Income for Counties and States" [accessed on September 28, 2010]. Available at http://www.census. gov/did/www/sahie/data/index.html
25. United States Bureau of the Census. 2006. "Health Insurance Coverage Status by Age, Race, Hispanic Origin, Sex and Income for Counties and States" [accessed on September 28, 2010]. Available at http://www.census. gov/did/www/sahie/data/index.html
26. United States Bureau of the Census. 2007. "Health Insurance Coverage Status by Age, Race, Hispanic Origin, Sex and Income for Counties and States" [accessed on September 28, 2010]. Available at http://www.census. gov/did/www/sahie/data/index.html
27. Weissman, J. S., C. Gatsonis, and, A. M. Epstein,. 1992. " Rates of Avoidable Hospitalization by Insurance Status in Massachusetts and Maryland. Journal of American Medical Association 268 (17): 2388-94.
28. White, H., 1980. " A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. Econometrica 48 (4): 817-38.
29. Yin, W., A. Basu, J. X. Zhang, A. Rabbani, D. O. Meltzer, and, G. C. Alexander,. 2008. " The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures. Annals of Internal Medicine 148 (3): 169-77. (Pubitemid 351665504)
30. Zhang, Y., J. M. Donohue, J. R. Lave, G. O'Donnell, and, J. P. Newhouse,. 2009. " The Effect of Medicare Part D on Drug and Medical Spending. New England Journal of Medicine 361 (1): 52-61.